+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Investigation Report on China's Liraglutide Market 2021-2025

  • PDF Icon

    Report

  • 50 Pages
  • June 2021
  • Region: China
  • China Research & Intelligence
  • ID: 5342822
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, developed by Novo Nordisk A/S. Its product VICTOZA firstly launched in the EU in July 2009 and firstly approved to enter the Chinese market in 2011. Liraglutide is a medication used for the treatment of type 2 diabetes or obesity. As one of the most important GLP-1 receptor agonists, Liraglutide is the only human GLP-1 analog that has been shown to reduce the risk of cardiovascular death. By 2020, Novo Nordisk A/S is the only manufacturer in the Chinese Liraglutide market.





According to the market research, Liraglutide sales have increased year by year from 2016 to 2020. Liraglutide was included in the medical insurance reimbursement catalog in 2017. Therefore, the sales value growth in 2018 was the most obvious, from CNY51.98 million in 2017 to CNY114.39 million in 2018. The annual growth rate is about 120.05%. Due to the impact of the COVID-19 epidemic, the sales value of China's Liraglutide reached CNY286.73 million in 2020 and the growth rate is 30.43%, which is less than that in 2019. The CAGR of Liraglutide's sales value from 2016 to 2020 is 61.87% in China.

The analyst expects that the sales value of Liraglutide will have a recovery growth from 2021 to 2025 with the effective alleviation of the COVID-19 epidemic. The patent of Liraglutide has expired, and the drug registration application for Liraglutide injection produced by Shenzhen Hanyu Pharmaceutical Co., Ltd. has been officially accepted in 2019. Since then, the number of manufacturers will gradually increase, the market will continue to expand, and the price will decline, which will cause the increase in sales and sale volume of Liraglutide. In addition, the huge patient population will also enable the Liraglutide market to continue to expand. In China, on average, there is 1 diabetic in 10 adults, and type 2 diabetic patients account for more than 90% of all diabetic patients. The huge number of patients has also increased the demand for Liraglutide. Therefore, its sales will continue to grow as the market expands in the future.

Topics Covered:

  • The impact of COVID-19 on China's Liraglutide market
  • Sales value of China's Liraglutide 2016-2020
  • Competitive landscape of China's Liraglutide market
  • Prices of Liraglutide in China
  • Prices of Liraglutide in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Liraglutide market
  • Prospect of China's Liraglutide market from 2021 to 2025
Frequently Asked Questions about the Chinese Liraglutide Market

What is the estimated value of the Chinese Liraglutide Market?

The Chinese Liraglutide Market was estimated to be valued at CNY 41.76 Million in 2016.

What is the growth rate of the Chinese Liraglutide Market?

The growth rate of the Chinese Liraglutide Market is 49.3%, with an estimated value of CNY 1542.1 Million by 2025.

What is the forecasted size of the Chinese Liraglutide Market?

The Chinese Liraglutide Market is estimated to be worth CNY 1542.1 Million by 2025.

Who are the key companies in the Chinese Liraglutide Market?

Key companies in the Chinese Liraglutide Market include Novo Nordisk A/S.

Table of Contents

1 Relevant Concepts of Liraglutide
1.1 Indications for Liraglutide
1.2 Development of Liraglutide in China
1.3 Governmental Approval of Liraglutide in China
1.4 The Impact of COVID-19 on Liraglutide sales in China
2 Sales of Liraglutide in China, 2016-2020
2.1 Sales Value of Liraglutide
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Liraglutide
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Liraglutide by Dosage Form in China, 2016-2020
2.3.1 Injection
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Liraglutide Manufacturers in China, 2016-2020
3.1 Analysis of Market Share of Major Liraglutide Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Novo Nordisk A/S
3.2.1 Enterprise Profile
3.2.2 Sales of VICTOZA (Novo Nordisk A/S's Liraglutide) in China
4 Prices of Liraglutide for Different Manufacturers in China, 2020-2021
4.1 Novo Nordisk A/S (VICTOZA)
4.2 Analysis of Other Enterprises
5 Prospect of Chinese Liraglutide drug Market, 2021-2025
5.1 Influential Factors of Chinese Liraglutide Market Development
5.1.1 The Impact of COVID-19 on Chinese Liraglutide Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Patent Information About Liraglutide Injection Registration in China
Chart Sales Value of Liraglutide Injection over the World
Chart Sales Value of Liraglutide Injection in China, 2016-2020
Chart Sales Value of Liraglutide Injection in China by Region, 2016-2020
Chart Sales Volume of Liraglutide Injection in China, 2016-2020
Chart Sales Volume of Liraglutide Injection in China by Region, 2016-2020
Chart Market Share by Sales Value of Top Liraglutide Manufacturers in China, 2016-2020
Chart Sales Value and Volume of VICTOZA in China, 2016-2020
Chart Referential Prices of VICTOZA in China, 2020-2021
Chart Forecast on Sales Value of Liraglutide in China, 2021-2025
Chart Forecast on Sales Volume of Liraglutide in China, 2021-2025

Samples

Loading
LOADING...

Companies Mentioned

  • Novo Nordisk A/S

Methodology

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...